logo
Breadcrumbs Image

Spinal Muscular Atrophy Medicine Market

Spinal Muscular Atrophy Medicine Market

Global Spinal Muscular Atrophy Medicine Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027


Date: Apr-2021 | Id: MACRC-62311 | Geographical Scope: Global | Publisher: Mnemonics Research

The global Spinal Muscular Atrophy Medicine market is expected to reach US$ XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on Mnemonics Rresearch newly published report.
 The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
 
 By Market Verdors:
 Astellas Pharma Inc.
 AveXis, Inc.
 Bioblast Pharma Ltd.
 Cytokinetics, Inc. 24
 F. Hoffmann-La Roche Ltd.
 Genethon
 Genzyme Corporation
 GMP-Orphan SAS
 Ionis Pharmaceuticals, Inc.
 Longevity Biotech, Inc
 Neurodyn Inc.
 Neurotune AG
 Novartis AG
 Sarepta Therapeutics, Inc.
 Voyager Therapeutics, Inc.
 Vybion, Inc.
 WAVE Life Sciences Ltd.
 
 By Types:
 LMI-070
 ND-602
 NT-1654
 Nusinersen
 NXD-30001
 Others
 
 By Applications:
 Hospital
 Clinic
 Others
 
 Key Indicators Analysed
 Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
 Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
 Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
 Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology
 Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
 
 Key Reasons to Purchase
 To gain insightful analyses of the market and have comprehensive understanding of the global  market and its commercial landscape.
 Assess the production processes, major issues, and solutions to mitigate the development risk.
 To understand the most affecting driving and restraining forces in the market and its impact in the global market.
 Learn about the market strategies that are being adopted by leading respective organizations.
 To understand the future outlook and prospects for the market.
 Besides the standard structure reports, we also provide custom research according to specific requirements.

Get Started with Request an Overview
Get Started with Download Brochure
Get Started with Request Methodology
Get Started with Share Customization
Get Started with Submit RFP
1 Report Overview
 1.1 Study Scope and Definition
 1.2 Research Methodology
 1.2.1 Methodology/Research Approach
 1.2.2 Data Source
 1.3 Key Market Segments
 1.4 Players Covered: Ranking by Spinal Muscular Atrophy Medicine Revenue
 1.5 Market Analysis by Type
 1.5.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type: 2021 VS 2027
 1.5.2 LMI-070
 1.5.3 ND-602
 1.5.4 NT-1654
 1.5.5 Nusinersen
 1.5.6 NXD-30001
 1.5.7 Others
 1.6 Market by Application
 1.6.1 Global Spinal Muscular Atrophy Medicine Market Share by Application: 2022-2027
 1.6.2 Hospital
 1.6.3 Clinic
 1.6.4 Others
 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2021 and 2022 Projections
 1.7.2 Covid-19 Impact: Commodity Prices Indices
 1.7.3 Covid-19 Impact: Global Major Government Policy
 1.8 Study Objectives
 1.9 Years Considered
 2 Global Spinal Muscular Atrophy Medicine Market Trends and Growth Strategy
 2.1 Market Top Trends
 2.2 Market Drivers
 2.3 Market Challenges
 2.4 Porter’s Five Forces Analysis
 2.5 Market Growth Strategy
 2.6 SWOT Analysis
 3 Global Spinal Muscular Atrophy Medicine Market Players Profiles
 3.1 Astellas Pharma Inc.
 3.1.1 Astellas Pharma Inc. Company Profile
 3.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.2 AveXis, Inc.
 3.2.1 AveXis, Inc. Company Profile
 3.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.3 Bioblast Pharma Ltd.
 3.3.1 Bioblast Pharma Ltd. Company Profile
 3.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Specification
 3.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.4 Cytokinetics, Inc. 24
 3.4.1 Cytokinetics, Inc. 24 Company Profile
 3.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Specification
 3.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.5 F. Hoffmann-La Roche Ltd.
 3.5.1 F. Hoffmann-La Roche Ltd. Company Profile
 3.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Specification
 3.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.6 Genethon
 3.6.1 Genethon Company Profile
 3.6.2 Genethon Spinal Muscular Atrophy Medicine Product Specification
 3.6.3 Genethon Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.7 Genzyme Corporation
 3.7.1 Genzyme Corporation Company Profile
 3.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Specification
 3.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.8 GMP-Orphan SAS
 3.8.1 GMP-Orphan SAS Company Profile
 3.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Specification
 3.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.9 Ionis Pharmaceuticals, Inc.
 3.9.1 Ionis Pharmaceuticals, Inc. Company Profile
 3.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.10 Longevity Biotech, Inc
 3.10.1 Longevity Biotech, Inc Company Profile
 3.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Specification
 3.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.11 Neurodyn Inc.
 3.11.1 Neurodyn Inc. Company Profile
 3.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.12 Neurotune AG
 3.12.1 Neurotune AG Company Profile
 3.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Specification
 3.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.13 Novartis AG
 3.13.1 Novartis AG Company Profile
 3.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Specification
 3.13.3 Novartis AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.14 Sarepta Therapeutics, Inc.
 3.14.1 Sarepta Therapeutics, Inc. Company Profile
 3.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.15 Voyager Therapeutics, Inc.
 3.15.1 Voyager Therapeutics, Inc. Company Profile
 3.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.16 Vybion, Inc.
 3.16.1 Vybion, Inc. Company Profile
 3.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Specification
 3.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 3.17 WAVE Life Sciences Ltd.
 3.17.1 WAVE Life Sciences Ltd. Company Profile
 3.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Specification
 3.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
 4 Global Spinal Muscular Atrophy Medicine Market Competition by Market Players
 4.1 Global Spinal Muscular Atrophy Medicine Production Capacity Market Share by Market Players (2016-2021)
 4.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Market Players (2016-2021)
 4.3 Global Spinal Muscular Atrophy Medicine Average Price by Market Players (2016-2021)
 5 Global Spinal Muscular Atrophy Medicine Production by Regions (2016-2021)
 5.1 North America
 5.1.1 North America Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.1.2 Spinal Muscular Atrophy Medicine Key Players in North America (2016-2021)
 5.1.3 North America Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.1.4 North America Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.2 East Asia
 5.2.1 East Asia Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.2.2 Spinal Muscular Atrophy Medicine Key Players in East Asia (2016-2021)
 5.2.3 East Asia Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.2.4 East Asia Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.3 Europe
 5.3.1 Europe Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.3.2 Spinal Muscular Atrophy Medicine Key Players in Europe (2016-2021)
 5.3.3 Europe Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.3.4 Europe Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.4 South Asia
 5.4.1 South Asia Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.4.2 Spinal Muscular Atrophy Medicine Key Players in South Asia (2016-2021)
 5.4.3 South Asia Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.4.4 South Asia Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.5 Southeast Asia
 5.5.1 Southeast Asia Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.5.2 Spinal Muscular Atrophy Medicine Key Players in Southeast Asia (2016-2021)
 5.5.3 Southeast Asia Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.5.4 Southeast Asia Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.6 Middle East
 5.6.1 Middle East Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.6.2 Spinal Muscular Atrophy Medicine Key Players in Middle East (2016-2021)
 5.6.3 Middle East Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.6.4 Middle East Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.7 Africa
 5.7.1 Africa Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.7.2 Spinal Muscular Atrophy Medicine Key Players in Africa (2016-2021)
 5.7.3 Africa Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.7.4 Africa Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.8 Oceania
 5.8.1 Oceania Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.8.2 Spinal Muscular Atrophy Medicine Key Players in Oceania (2016-2021)
 5.8.3 Oceania Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.8.4 Oceania Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.9 South America
 5.9.1 South America Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.9.2 Spinal Muscular Atrophy Medicine Key Players in South America (2016-2021)
 5.9.3 South America Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.9.4 South America Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 5.10 Rest of the World
 5.10.1 Rest of the World Spinal Muscular Atrophy Medicine Market Size (2016-2021)
 5.10.2 Spinal Muscular Atrophy Medicine Key Players in Rest of the World (2016-2021)
 5.10.3 Rest of the World Spinal Muscular Atrophy Medicine Market Size by Type (2016-2021)
 5.10.4 Rest of the World Spinal Muscular Atrophy Medicine Market Size by Application (2016-2021)
 6 Global Spinal Muscular Atrophy Medicine Consumption by Region (2016-2021)
 6.1 North America
 6.1.1 North America Spinal Muscular Atrophy Medicine Consumption by Countries
 6.1.2 United States
 6.1.3 Canada
 6.1.4 Mexico
 6.2 East Asia
 6.2.1 East Asia Spinal Muscular Atrophy Medicine Consumption by Countries
 6.2.2 China
 6.2.3 Japan
 6.2.4 South Korea
 6.3 Europe
 6.3.1 Europe Spinal Muscular Atrophy Medicine Consumption by Countries
 6.3.2 Germany
 6.3.3 United Kingdom
 6.3.4 France
 6.3.5 Italy
 6.3.6 Russia
 6.3.7 Spain
 6.3.8 Netherlands
 6.3.9 Switzerland
 6.3.10 Poland
 6.4 South Asia
 6.4.1 South Asia Spinal Muscular Atrophy Medicine Consumption by Countries
 6.4.2 India
 6.5 Southeast Asia
 6.5.1 Southeast Asia Spinal Muscular Atrophy Medicine Consumption by Countries
 6.5.2 Indonesia
 6.5.3 Thailand
 6.5.4 Singapore
 6.5.5 Malaysia
 6.5.6 Philippines
 6.6 Middle East
 6.6.1 Middle East Spinal Muscular Atrophy Medicine Consumption by Countries
 6.6.2 Turkey
 6.6.3 Saudi Arabia
 6.6.4 Iran
 6.6.5 United Arab Emirates
 6.7 Africa
 6.7.1 Africa Spinal Muscular Atrophy Medicine Consumption by Countries
 6.7.2 Nigeria
 6.7.3 South Africa
 6.8 Oceania
 6.8.1 Oceania Spinal Muscular Atrophy Medicine Consumption by Countries
 6.8.2 Australia
 6.9 South America
 6.9.1 South America Spinal Muscular Atrophy Medicine Consumption by Countries
 6.9.2 Brazil
 6.9.3 Argentina
 6.10 Rest of the World
 6.10.1 Rest of the World Spinal Muscular Atrophy Medicine Consumption by Countries
 7 Global Spinal Muscular Atrophy Medicine Production Forecast by Regions (2022-2027)
 7.1 Global Forecasted Production of Spinal Muscular Atrophy Medicine (2022-2027)
 7.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine (2022-2027)
 7.3 Global Forecasted Price of Spinal Muscular Atrophy Medicine (2022-2027)
 7.4 Global Forecasted Production of Spinal Muscular Atrophy Medicine by Region (2022-2027)
 7.4.1 North America Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.2 East Asia Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.3 Europe Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.4 South Asia Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.5 Southeast Asia Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.6 Middle East Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.7 Africa Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.8 Oceania Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.9 South America Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.4.10 Rest of the World Spinal Muscular Atrophy Medicine Production, Revenue Forecast (2022-2027)
 7.5 Forecast by Type and by Application (2022-2027)
 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
 7.5.2 Global Forecasted Consumption of Spinal Muscular Atrophy Medicine by Application (2022-2027)
 8 Global Spinal Muscular Atrophy Medicine Consumption Forecast by Regions (2022-2027)
 8.1 North America Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.2 East Asia Market Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.3 Europe Market Forecasted Consumption of Spinal Muscular Atrophy Medicine by Countriy
 8.4 South Asia Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.5 Southeast Asia Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.6 Middle East Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.7 Africa Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.8 Oceania Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.9 South America Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 8.10 Rest of the world Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
 9 Global Spinal Muscular Atrophy Medicine Sales by Type (2016-2027)
 9.1 Global Spinal Muscular Atrophy Medicine Historic Market Size by Type (2016-2021)
 9.2 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Type (2022-2027)
 10 Global Spinal Muscular Atrophy Medicine Consumption by Application (2016-2027)
 10.1 Global Spinal Muscular Atrophy Medicine Historic Market Size by Application (2016-2021)
 10.2 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Application (2022-2027)
 11 Global Spinal Muscular Atrophy Medicine Manufacturing Cost Analysis
 11.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis
 11.1.1 Key Raw Materials
 11.2 Proportion of Manufacturing Cost Structure
 11.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
 12 Global Spinal Muscular Atrophy Medicine Marketing Channel, Distributors, Customers and Supply Chain
 12.1 Marketing Channel
 12.2 Spinal Muscular Atrophy Medicine Distributors List
 12.3 Spinal Muscular Atrophy Medicine Customers
 12.4 Spinal Muscular Atrophy Medicine Supply Chain Analysis
 13 Analyst's Viewpoints/Conclusions
 14 Disclaimer

Add to Cart

Single User

$ 2450.00

Site License

$ 3675.00

Enterprisewide

$ 4900.00